A Single Center Real-world Observational Study of Response to Dacarbazine or Dacarbazine Combinations in Metastatic Melanoma Refractory to Immunotherapy
Dacarbazine-based chemotherapy retains modest activity in selected patients with advanced melanoma in the immunotherapy-refractory setting, and further multicenter studies are required to define predictive biomarkers and optimize patient selection.
Abstract
Background/Aim: Outcomes in cutaneous melanoma have improved significantly with the introduction of immune checkpoint inhibitors (ICIs). However, a subset of patients remains refractory to ICIs. Dacarbazine is a well-established chemotherapy option for melanoma, and National Institute for Health and Clinical Excellence (NICE) guidelines continue to recommend it as a systemic anticancer treatment for unresectable stage III and IV melanoma. With the introduction of ICI and targeted treatments, BRAF/MEK inhibitors, the role of conventional chemotherapy has become less clear. This study aimed to determine real-world outcomes with dacarbazine, alone or in combination chemotherapy, in patients with advanced melanoma treated in this setting. Patients and Methods: We conducted a retrospective single-centre observational study of patients with unresectable stage IV melanoma treated with dacarbazine alone or in combination with cisplatin between January 2014 and June 2023. Outcomes included overall survival (OS), progression-free survival (PFS), disease control rate (DCR), and time-to-treatment failure (TTF), assessed using RECIST 1.1 criteria where available. Results: Forty patients were included. Median age was 64 years (range=28-82 years). Median OS was 7.6 months, median PFS was 2.9 months, and median TTF was 3.5 months. DCR was 37.8%, with partial response in 27% and stable disease in 10.8%. No complete responses were observed and 30% of patients survived ≥12 months. Conclusion: Dacarbazine-based chemotherapy retains modest activity in selected patients with advanced melanoma in the immunotherapy-refractory setting. Further multicenter studies are required to define predictive biomarkers and optimize patient selection.
In real-world clinical practice, BRAF/MEK targeted therapy has demonstrated effectiveness in the Russian patient population, with outcomes consistent with those observed in randomized clinical trials, despite substantial population heterogeneity and the inclusion of patients with unfavorable prognostic factors.
I. Samoylenko, K. Orlova, N. V. Leushina et al.· Meditsinskiy sovet = Medical...· 0 citations
PURPOSE
Mucosal melanoma (MM) is a rare subtype of melanoma with inferior response rates and outcomes to immunotherapy. Vascular endothelial growth factor (VEGF) signaling may contribute to immune resistance and represents a potential therapeutic target. We evaluated nivolumab plus axitinib in untreated, advanced MM in...
S. Lochrin, H. Kalvin, Monica F. Chen et al.· Clinical Cancer Research· 0 citations
BACKGROUND
Nivolumab-relatlimab, a dual immune checkpoint inhibitor targeting PD-1 and LAG-3, has demonstrated improved outcomes compared with nivolumab monotherapy in previously untreated advanced melanoma. However, real-world data in broader and less selected populations remain limited.
METHODS
We conducted a multi...
N. Asher, Moti Avner, Nadav Goldberg et al.· European Journal of Cancer· 0 citations
Abstract Background Metastatic uveal melanoma (mUM) carries a poor prognosis, with low response rates to checkpoint inhibitors. The phase III first-line IMCgp100-202 trial established tebentafusp, a bi-specific T cell engager, as the first treatment to demonstrate a survival benefit in mUM. Here, we report retrospectiv...
Magdalene Joseph, J. Tharakan, J. Proudfoot-Jones et al.· The Oncologist· 0 citations
Background: Immune checkpoint inhibitors have demonstrated remarkable efficacy in treating melanoma in various regions. However, in countries with a non-continuous drug supply, ensuring consistent access to pembrolizumab becomes a critical concern.
Objective: This study was to evaluate the efficacy of Pembrolizumab in...
M. Mobarek, A. Al-Samaraee, M. J. Ibrahim et al.· Bangladesh Journal of Infect...· 0 citations
In this retrospective analysis, treatment BPD was not associated with an improved prognosis compared to 2L therapy and there is a need to improve and implement criteria to select patients who truly benefit from this treatment approach.
A. Oseledchyk, L. Häcker, A. Schmitt et al.· Oncology Research and Treatm...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.